277 related articles for article (PubMed ID: 31844595)
21. Construction of a model to predict the prognosis of patients with cholangiocarcinoma using alternative splicing events.
Wu HY; Wei Y; Liu LM; Chen ZB; Hu QP; Pan SL
Oncol Lett; 2019 Nov; 18(5):4677-4690. PubMed ID: 31611977
[TBL] [Abstract][Full Text] [Related]
22. Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma.
Xu Q; Xu H; Deng R; Li N; Mu R; Qi Z; Shen Y; Wang Z; Wen J; Zhao J; Weng D; Huang W
Cancer Cell Int; 2021 Apr; 21(1):190. PubMed ID: 33794886
[TBL] [Abstract][Full Text] [Related]
23. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.
Zhang D; Zou D; Deng Y; Yang L
J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089
[TBL] [Abstract][Full Text] [Related]
24. Development of a Nomogram With Alternative Splicing Signatures for Predicting the Prognosis of Glioblastoma: A Study Based on Large-Scale Sequencing Data.
Wang Z; Gao L; Guo X; Feng C; Lian W; Deng K; Xing B
Front Oncol; 2020; 10():1257. PubMed ID: 32793502
[No Abstract] [Full Text] [Related]
25. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data.
Xu N; Ke ZB; Lin XD; Lin F; Chen SH; Wu YP; Chen YH; Wei Y; Zheng QS
Aging (Albany NY); 2020 Mar; 12(6):4996-5009. PubMed ID: 32217810
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer.
Liu M; Khushbu RA; Chen P; Hu HY; Tang N; Ou-Yang DJ; Wei B; Zhao YX; Huang P; Chang S
Front Oncol; 2021; 11():705929. PubMed ID: 34722250
[TBL] [Abstract][Full Text] [Related]
27. Identification of an alternative splicing signature as an independent factor in colon cancer.
Chen H; Luo J; Guo J
BMC Cancer; 2020 Sep; 20(1):904. PubMed ID: 32962686
[TBL] [Abstract][Full Text] [Related]
28. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Value and Potential Role of Alternative mRNA Splicing Events in Cervical Cancer.
Shao XY; Dong J; Zhang H; Wu YS; Zheng L
Front Genet; 2020; 11():726. PubMed ID: 32793282
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a survival model based on autophagy-associated genes for predicting prognosis of hepatocellular carcinoma.
Yang W; Niu L; Zhao X; Duan L; Li Y; Wang X; Zhang Y; Zhou W; Liu J; Zhao Q; Han Y; Fan D; Hong L
Am J Transl Res; 2020; 12(10):6705-6722. PubMed ID: 33194067
[TBL] [Abstract][Full Text] [Related]
31. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
Front Genet; 2020; 11():534. PubMed ID: 32595697
[TBL] [Abstract][Full Text] [Related]
32. Identifying Dendritic Cell-Related Genes Through a Co-Expression Network to Construct a 12-Gene Risk-Scoring Model for Predicting Hepatocellular Carcinoma Prognosis.
Huang C; Jiang X; Huang Y; Zhao L; Li P; Liu F
Front Mol Biosci; 2021; 8():636991. PubMed ID: 34109210
[TBL] [Abstract][Full Text] [Related]
33. Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma.
Sun JR; Kong CF; Lou YN; Yu R; Qu XK; Jia LQ
Front Genet; 2020; 11():796. PubMed ID: 32793288
[TBL] [Abstract][Full Text] [Related]
34. Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma.
Jiang Y; Zhang C; Chen Y; Zhao S; He Y; He J
Cancer Med; 2023 Feb; 12(4):4895-4906. PubMed ID: 36031798
[TBL] [Abstract][Full Text] [Related]
35. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
[TBL] [Abstract][Full Text] [Related]
36. Construction of a breast cancer prognosis model based on alternative splicing and immune infiltration.
Zhang D; Lu W; Zhuo Z; Mei H; Wu X; Cui Y
Discov Oncol; 2022 Aug; 13(1):78. PubMed ID: 35988113
[TBL] [Abstract][Full Text] [Related]
37. Alternative splicing events are prognostic in hepatocellular carcinoma.
Chen QF; Li W; Wu P; Shen L; Huang ZL
Aging (Albany NY); 2019 Jul; 11(13):4720-4735. PubMed ID: 31301224
[TBL] [Abstract][Full Text] [Related]
38. Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma.
Xing L; Zhang X; Tong D
DNA Cell Biol; 2019 Jul; 38(7):627-638. PubMed ID: 31025877
[TBL] [Abstract][Full Text] [Related]
39. Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data.
Zhang D; Zhang W; Sun R; Huang Z
Bioengineered; 2021 Dec; 12(1):1091-1110. PubMed ID: 33783315
[TBL] [Abstract][Full Text] [Related]
40. Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods.
Cai Q; He B; Zhang P; Zhao Z; Peng X; Zhang Y; Xie H; Wang X
J Transl Med; 2020 Dec; 18(1):463. PubMed ID: 33287830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
